

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1645  
ITW

Applicant: Clifford P. Stanners et al.

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

Docket No.: 186.009US1

Filed: August 11, 2000

Examiner: Unknown



Serial No.: 09/637,530

Due Date: N/A

Group Art Unit: 1645

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ Communication Regarding Filing of Priority Document (1 Page).
- ☒ Certified Copy of Canadian Patent Application No.: 2,224,129 (34 Pages).

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
Customer Number 21186

By: William F. Prout  
Atty: William F. Prout  
Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 27<sup>th</sup> day of September, 2004.

PATRICIA A. HULTMAN  
Name

Patricia A. Hultman  
Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
(GENERAL)

**BEST AVAILABLE COPY**



S/N 09/637,530

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Clifford P. Stanners et al.	Examiner:	Unknown
Serial No.:	09/637,530	Group Art Unit:	1645
Filed:	August 11, 2000	Docket:	186.009US1
Title:	CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY		

COMMUNICATION REGARDING FILING OF  
PRIORITY DOCUMENT

Commissioner for Patents  
P.O.Box 1450  
Alexandria, VA 22313-1450

In accordance with the requirements for claiming right of priority under 35 U.S.C. 119, enclosed for filing in connection with the above-identified application is a certified copy of Applicant's prior application, Canadian Patent Application No. 2,224,129, filed February 12, 1998.

Respectfully submitted,

CLIFFORD P. STANNERS ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6968

Date September 27, 2004 By William F Prout  
William F Prout  
Reg. No. 33,995

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 27th day of September, 2004.

Patricia A. Hume  
Name

[Signature]  
Signature



Office de la propriété  
intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An Agency of  
Industry Canada

*Bureau canadien  
des brevets  
Certification*

*Canadian Patent  
Office  
Certification*

La présente atteste que les documents  
ci-joints, dont la liste figure ci-dessous,  
sont des copies authentiques des docu-  
ments déposés au Bureau des brevets.

This is to certify that the documents  
attached hereto and identified below are  
true copies of the documents on file in  
the Patent Office.

Specification and Drawings, as originally filed, with Application for Patent Serial No:  
**2,224,129**, on February 12, 1998, by **McGILL UNIVERSITY**, assignee of Clifford P.  
Stanners, Chris Ilantzis, Cosmé Ordonez-Garcia, Maryam Taheri and Robert A. Screatton,  
for "Anti-Onc Cea-Based Cancer Therapy"

**CERTIFIED COPY OF  
PRIORITY DOCUMENT**

*[Signature]*

Agent certificateur/Certifying Officer

August 25, 2004

Date

Canada

(CIPQ 68)  
31-03-04

OPIC  CIPO

**ABSTRACT OF THE INVENTION**

The present invention relates to a novel cancer therapy based on the direct or indirect downregulation of endogenous CEA/NCA which plays an instrumental role in malignant progression through its differentiation-blocking activity on normal cells. More precisely, there is provided an inhibiting CEA/NCA sequence, which comprises antisense cDNA sequences which hybridize to at least one domain of CEA/NCA selected from the group consisting of the cDNA sequences of CEA and NCA to reduce the expression of endogenous CEA/NCA when administered to a cancer patient.

ANTI-ONC CEA-BASED CANCER THERAPYBACKGROUND OF THE INVENTION(a) Field of the Invention

5           The invention relates to a novel cancer therapy based on the direct or indirect downregulation of endogenous CEA/NCA which plays an instrumental role in malignant progression through its differentiation-blocking activity on normal cells.

10   (b) Description of Prior Art

          The long-term cure rates for cancers at many sites treated by present means, such as surgery, radiation and chemotherapy, are often unacceptably low. Due to the common presence of metastases derived from  
15 the primary tumor, it is impossible to treat most cancers effectively with surgery and radiation alone. Systemic chemotherapy is effective in some cases but is often too toxic to permit the use of the doses required for cure. Novel treatments based on molecular  
20 differences between cancer and normal cells are required. Such treatments would likely be non-toxic and, since they would be based on different principles from the commonly used treatments, would be expected to be synergistic with them, giving more effective  
25 combined treatment.

          Tumor cells at many sites, including colon, breast, lung, cervix, ovary, bladder and pancreas express large amounts of carcinoembryonic antigen (CEA) and/or the closely related family member, NCA, on their  
30 surfaces. The expression of these glycoproteins, especially CEA, in normal cells is very limited. This represents the basis for the wide clinical use of CEA as a blood tumor marker. Since the majority of human cancers show up-regulation of CEA/NCA, any therapy  
35 based on this fact has potential application to an

- 2 -

immense number of cancer patients. This upregulation in so many types of cancer led us to suggest that CEA and NCA could actually contribute directly to tumorigenicity. We first showed that CEA (Benchimol et al, Cell 57:327-334, 1989) and NCA (Zhou et al, Cell Growth Differ. 1:209-215, 1990) function as intercellular adhesion molecules. Although CEA had been previously considered as an inert marker of tumorigenicity, we suggested that inappropriate CEA/NCA expression in cells still capable of proliferation could cause a distortion of tissue architecture (which is determined by adhesion molecules) and an inhibition of terminal differentiation that normally removes cells from the pool of cells with potential to proliferate, thus contributing directly to malignant progression.

In agreement with this hypothesis, we have shown that CEA and NCA expression in transfected myoblasts can inhibit terminal myogenic differentiation and promote tumorigenicity. Peptides representing the adhesion domains of CEA can release the myogenic differentiation block in CEA-transfected myoblasts, indicating the necessity of CEA-CEA interactions for the inhibition of terminal differentiation.

In the present invention, the inhibition of terminal differentiation by CEA/NCA over-expression has been demonstrated to apply to the adipogenic differentiation of mouse fibroblasts, to the neuronal differentiation of mouse embryonal carcinoma cells and to the differentiation and polarization of human colonocytes. CEA/NCA over-expression has also been shown to distort tissue architecture and to inhibit anoikis (apoptosis of anchorage-free cells). These carcinogenetic effects of CEA expression on colonocytes can be reversed by down-regulating CEA. The inhibition of differentiation depends on both interactions between

- 3 -

the external domains of CEA and on the presence of a CEA-determined glycoposphatidyl-inositol (GPI) membrane anchor. Novel treatments based on reversal of the carcinogenetic effects of CEA/NCA would be highly desirable since they would be precisely targeted to tumor cells expressing these molecules and should therefore be applicable to a large proportion of human cancers.

It would be highly desirable to provide a novel cancer therapy based on the direct or indirect downregulation of endogenous CEA/NCA which plays an instrumental role in malignant progression, through its differentiation-blocking activity on normal cells.

#### 15 SUMMARY OF THE INVENTION

One aim of the present invention is to provide a novel cancer therapy based on the downregulation of CEA/NCA which we show plays an instrumental role in malignant progression. This treatment based on this property of CEA/NCA is precisely targeted to tumor cells expressing these molecules and is therefore applicable to a large proportion of human cancers.

The differentiation-blocking activity of the inappropriate over-expression of endogenous CEA/NCA molecules, by a complex molecular pathway, renders cells capable of proliferations in an abnormal embryonic fashion.

In accordance with the present invention, there exists four (4) different routes for interference with the tumorigenic effects of CEA/NCA:

1. Antisense cDNA constructs and oligonucleotides reduce the expression of CEA/NCA when administered directly or by gene therapy to a cancer patient, which restores differentiation completely and thus inhibits tumorigenicity.

- 4 -

2. Antibodies raised against subdomains of CEA/NCA, small peptides and derived mimetics which all interact with precise subdomains of CEA/NCA that are involved in the differentiation-blocking activity associated with malignant progression. The antibodies, peptides and derived mimetics when administered to cancer patients will restore differentiation completely and thus inhibit tumorigenicity.
3. "Shankless anchors", consisting of the GPI anchor of CEA without the external domains, interfere with the differentiation-inhibiting activity of CEA/NCA and can be administered either directly or by gene therapy to a cancer patient. The "shankless anchors" inhibit the differentiation-blocking activity of the endogenous CEA/NCA molecules by competing with CEA/NCA for the elements of the molecular pathway required for the CEA/NCA effect.
4. Cell surface receptors involved in extracellular matrix (ECM) binding, integrins, are involved in the differentiation-blocking activity of CEA/NCA molecules. The particular integrins, including  $\alpha_5\beta_1$ , have been identified. Inhibition of the changes that these molecules undergo as a result of CEA/NCA activity could release the CEA/NCA-imposed differentiation block.

All these routes lead to new useful clinical agents capable of removing tumor cells by inducing their terminal differentiation, thus effectively killing tumor cells by a mechanism distinct from that of cytotoxic drugs.

In accordance with the present invention there is provided an inhibiting CEA/NCA sequence, which



- 5 -

comprises antisense cDNA sequences which hybridize to at least one domain of CEA/NCA selected from the group consisting of the cDNA sequences of CEA and NCA to reduce the expression of endogenous CEA/NCA when administered to a cancer patient.

In accordance with the present invention there is also provided an inhibiting CEA/NCA sequence of the present invention, wherein the sequence is an antisense cDNA or an antisense oligonucleotide.

In accordance with the present invention there is also provided anti-CEA/NCA antibodies, which comprises antibodies raised against subdomains of CEA/NCA involved in the differentiation-blocking activity associated with tumorigenicity, wherein the subdomains are selected from the group consisting of the sequences GYSWYK, N<sub>42</sub>RQII, Q<sub>80</sub>ND and other 30 sequences in the N terminal 107 amino acid domain, and sequences in the internal A3BB domain of CEA.

In accordance with the present invention there is also provided peptides and peptide-derived mimetics, which comprises peptide and peptide-derived mimetics interacting with subdomains of CEA/NCA involved in the differentiation-blocking activity associated with malignant, wherein the subdomains are selected from the group consisting of the sequences GYSWYK, N<sub>42</sub>RQII, Q<sub>80</sub>ND and other 30 sequences in the N-terminal 107 amino acid domain, and sequences in the internal A3BB domain of CEA.

In accordance with the present invention there is also provided a shankless anchor, which comprises a GPI anchor of CEA without the external domains attached to some carboxy terminal amino acids, wherein the GPI anchor interferes with downstream targets of endogenous CEA/NCA molecules to inhibit the differentiation-blocking activity of the endogenous CEA/NCA molecules.

- 6 -

In accordance with the present invention there is also provided a method to restore endogenous integrin function, which comprises the steps of:

5 a) administration of monoclonal antibodies that reverse the CEA/NCA-induced changes in integrin function; and

b) administration of peptides/mimetics that mimics the effect of the mAbs; thereby inhibiting the differentiation-blocking  
10 activity of the endogenous CEA/NCA molecules.

In accordance with the present invention there is also provided a drug screen assay to determine pharmaceutical agents which are capable of inhibiting the differentiation-blocking activity of the endogenous  
15 CEA/NCA molecules, which comprises the steps of:

a) screening for agents capable of releasing the myogenic differentiation block in rat L6 cells expressing CEA/NCA; and

20 b) screening for agents capable of restoring normal cellular and tissue architecture to human Caco-2 colonocytes aberrantly expressing high levels of CEA/NCA.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

25 Fig. 1 illustrates the effect of CEA/NCA overexpression in normal epithelial cells of colonic crypts which leads to a malignant tumor. The different sites of action of the routes 1, 2, 3 and 4 of the present invention as described above are indicated;

30 Fig. 2 illustrates that overexpression of NCA in human colorectal carcinoma cells, SW-1222, blocks the formation of glandular-like structures of polarized cells with central lumens in monolayer culture;

Fig. 3 (top) illustrates that overexpression of  
35 NCA blocks the formation in collagen gels of glandular

- 7 -

spheroids consisting of radially arranged polarized colonocytes with central lumens;

Fig. 3 (bottom) illustrates that overexpression of CEA and NCA in human colorectal carcinoma cells, Caco-2, blocks their polarization in monolayer culture leading to tumor-like multilayered structures with circumferential expression of CEA;

Fig. 4 illustrates that dome formation, due to vectorial transport of solvent from apical to basolateral surfaces of colonocytes and an indicator of polarization, is strongly inhibited by over-expression of CEA/NCA in Caco-2 colonocytes;

Fig. 5 illustrates that overexpression of NCA in SW-1222 cells causes loss of colonic glandular crypt formation with polarized cells facing a central lumen in a tissue architecture assay *in vivo*;

Fig. 6 illustrates that NCA overexpression inhibits anoikis of SW-1222 cells cultured in suspension;

Fig. 7 illustrates that down-regulation of CEA in SW-1222 cells results in a more normal, less tumorigenic phenotype;

Fig. 8 illustrates the quantitative evidence that down-regulation of CEA in SW-1222 cells results in more glandular spheroids with recognizable central lumens;

Fig. 9 illustrates the subdomains in the NH<sub>2</sub>-terminal N domain of CEA that are required for intercellular adhesion and for the myogenic differentiation block. The quantitative effects of mutations in these subdomains on CEA-mediated adhesion and on CEA-mediated myogenic differentiation block are also shown;

Fig. 10 illustrates the photomicrographs of L6 transfectants indicated in Fig. 9, showing the extent

- 8 -

of myogenic differentiation in some of the subdomain mutants;

Fig. 11 illustrates that substitution of the normal trans-membrane domain of the BGP $\alpha$  molecule (Tm) with the GPI membrane domain of CEA converts BGP $\alpha$  from a molecule that has no effect on myogenic differentiation (upper micrograph) to one (denoted BC-2) that inhibits myogenic differentiation completely (lower micrograph); and

Fig. 12 illustrates that substitution of the carboxy-terminal GPI-determining domain of NCAM-125 with the GPI domain of CEA giving the hybrid construct, NCAM 125-CEA, converts NCAM from a molecule that has no effect on myogenic differentiation to one that inhibits myogenic differentiation completely.

#### **DETAILED DESCRIPTION OF THE INVENTION**

Although CEA had been previously considered as an inert marker of tumorigenicity, we suggested (Benchimol et al, 1989) that inappropriate CEA/NCA expression in cells still capable of proliferation could cause a distortion of tissue architecture and an inhibition of terminal differentiation which normally removes cells from the pool of cells with potential to proliferate, thus contributing directly to malignant progression.

Fig. 1 illustrates the effect of CEA/NCA in normal cells which leads to a malignant tumor and the different site of action of the routes 1, 2, 3 and 4 of the present invention as described above.

Also Fig. 1 illustrates the mechanism of action of the route 3 of the present invention, that is "shankless anchors".

The above hypothesis was tested in several model systems: CEA expression in rat myoblasts (by

transfection with CEA cDNA) was shown to block terminal myogenic differentiation completely (Eidelman et al, J. Cell Biol. 123:467-475, 1993); NCA had the same effect whereas a CEA family member that is down-regulated in cancer (BGP) had no effect (Rojas et al, Cell Growth Differ. 7:655-662, 1996); CEA expression inhibits terminal adipogenic differentiation of mouse adipocytes; CEA and NCA, but not BGP, expression inhibits the neuronal differentiation of mouse embryonal carcinoma cells; finally, human colorectal carcinoma cell lines, SW-1222 and Caco-2, that retain differentiation and polarization capacity, when forced by transfection to over-express CEA and NCA, lose their ability to form colonic crypt-like glandular structures with central lumens in both monolayer and spheroid culture and lose their ability to polarize, closely resembling the more progressed human colorectal carcinomas removed from patients (Figs. 2, 3 and 4). Human colorectal carcinoma cell line SW-1222, stably transfected with empty expression vector [SW(Hygro)] or with vector containing NCA cDNA and thereby overexpressing NCA by 5-10 fold (in proliferating cells) [SW-NCA<sup>↑</sup>], grown in monolayer culture show lumens with radially arranged polarized cells in the case of the control SW(Hygro) cells but not in the case of the SW-NCA<sup>↑</sup> cells (top, Fig. 2). Polarization of the control SW(hygro) cells is shown by the presence of rings of villin staining localized with microvilli at the lumens (bottom, Fig. 2). Thus the residual degree of glandular differentiation exhibited by the human SW-1222 colonocytes in monolayer is completely inhibited by over-expression of NCA (Fig. 2).

In Fig. 3(top), SW-1222(Hygro) cells grown in suspension in collagen gels form glandular spheroids consisting of radially arranged polarized colonocytes

- 10 -

with central lumens selectively stained with anti-NCA mAb, whereas SW-NCA<sup>+</sup> cells form only irregular non-polarized cell masses with generalized NCA staining and no lumens. In Fig. 3(bottom), human colorectal carcinoma cell line Caco-2, stably transfected with empty expression vector [Caco(Hygro)] or with vectors containing CEA cDNA and NCA cDNA [Caco CEA/NCA<sup>+</sup>] and thereby overexpressing CEA & NCA by 20 fold (in proliferating cells), were cultured for 17 days on solid support. Cultures were sectioned vertically and stained with hematoxylin to show cell nuclei or with anti-CEA mAb to show the polarized expression of CEA at the apical upper surfaces of the monolayer of columnar colonocytes. Note the multilayered (stratified) configuration with circumferential CEA staining of the Caco CEA/NCA<sup>+</sup> cells. Thus CEA/NCA over-expression destroys the normal monolayered architecture of polarized columnar colonocytes of Caco-2, giving a tissue architecture closely mimicking that of colon carcinomas.

In Fig. 4, dome formation, due to vectorial transport of solvent from apical to basolateral surfaces of colonocytes and an indicator of polarization, is strongly inhibited by over-expression of CEA/NCA in Caco-2 colonocytes. Domes can be seen as raised circular areas of cells in the photomicrograph of control Caco(Hygro) cells (upper left) but not in Caco CEA/NCA<sup>+</sup> cells (upper right).

In an assay, developed in our laboratory, that tests the ability of human colonocytes to conform to normal tissue architecture (Ilantzis & Stanners, In Vitro Cell. Dev. Biol.- Animal 33: 50-61, 1997), over-expression of NCA causes a marked deterioration of their capacity to form colonic crypts (Fig. 5). Sections of minicolons obtained from growth of mixed

- 11 -

aggregates of normal fetal rat colonocytes and 1% SW(Hygro) or SW-NCA<sup>+</sup> cells for 7-10 days under the kidney capsule of the nude mouse are shown in Fig. 5. The SW-1222 cells were identified by staining with an anti-CEA mAb. Note the dramatic deterioration of the quasi-normal tissue architecture of the SW(Hygro) cells as exemplified by rings of staining that are absent in the SW-NCA<sup>+</sup> cells over-expressing NCA.

In fact, we have shown that the cell surface levels of CEA and NCA on purified colonocytes from freshly excised colon carcinomas and adjacent normal tissue from patients, measured by FACS analysis, are markedly higher on the tumor cells relative to the normal cells and inversely correlated with the degree of differentiation of the tumors (Ilantzis et al, Lab Invest. 76(5):703-716, 1997); this represents clinical evidence in support of our hypothesis. Even microadenomas, the early precursors of colonic carcinomas showed upregulation of CEA and NCA in direct relation to their degree of dysplasia (Ilantzis et al, 1997).

In agreement with the suggestion that these effects of CEA/NCA over-expression could drive malignant progression, both the rat myoblasts (Screaton et al, J. Cell Biol. 137:939-952, 1997) and human CaCo-2 colonocytes transfected with CEA/NCA, but not with the empty transfection vector, produced tumors in nude mice with a strikingly reduced latent period.

The above results support the contention that CEA and NCA are general inhibitors of terminal cellular differentiation. We have evidence that they achieve this by interference with the function of integrins responsible for cell extracellular matrix interactions. The latter interactions are known to be required for many different types of cellular differentiation.

- 12 -

Furthermore, we have direct evidence that these CEA/NCA-induced perturbations in integrin function inhibit anoikis, the apoptotic process that is employed to destroy cells that do not conform to normal tissue architecture (Fig. 6). CEA/NCA over-expression inhibits  
5 anoikis. SW-1222 cells attached to a solid support, stained with DAPI to show nuclear morphology, demonstrate whole nuclei (upper left). When incubated in suspension, parental SW-1222 cells, SW(hygro) cells  
10 and SW-CEA↓ cells (with CEA expression down-regulated) all show fragmented nuclei, indicative of anoikis (apoptosis). SW-NCA↑ cells, expressing much higher levels of NCA, show whole nuclei when incubated in suspension, thus not demonstrating anoikis.

15 The overall picture, then, is one of CEA/NCA-induced inhibition of terminal cellular differentiation, cellular polarization and anoikis, and an accompanying loss of tissue architecture. The net effect of these CEA/NCA-induced cellular changes is to  
20 promote malignancy.

#### 1. Antisense Agents:

Importantly, human SW-1222 colon carcinoma cells transfected with a defective mutant of CEA and  
25 thereby actually producing less than normal levels of CEA, denoted SW-CEA↓ were more differentiated than the parental cells, in that they exhibited a more normal flat morphology in monolayer culture (Fig. 7) and more readily formed glandular spheroids in collagen gels  
30 (Fig. 8), thus indicating the possibility of reversal of the tumorigenicity of colonic carcinoma cells by forcing the down-regulation of CEA/NCA. Micrographs of control SW-1222 and SW-CEA↓ monolayer cultures are presented in Fig. 7, showing that down-regulation of  
35 CEA (see FACS profiles for cells stained with



- 13 -

fluorescent CEA-specific mAb, D-14) results in a more normal, flatter morphology. The SW-CEA $\downarrow$  line was obtained by stable transfection with the defective N-domain deletion mutant,  $\Delta$ NCEA (Eidelman et al, 1993) (Fig. 7).

Such down regulation could be achieved by the application of CEA/NCA anti-sense oligonucleotides to tumors or gene therapy with CEA/NCA antisense cDNA constructs.

## 2. Antibodies, Peptides and Mimetics:

The myogenic differentiation-blocking ability of CEA, at least, can be reversed by interference with the adhesion domains of CEA (the N and A3B3 domains - Zhou et al, J. Cell Biol. 122: 951-960) using domain-specific peptides made in bacteria or by a deletion in the N-terminal domain (Eidelman et al, J. Cell Biol. 123:467-475, 1993), indicating the necessity of CEA-CEA interaction for the effect. In fact, the  $\Delta$ NCEA deletion mutant that is defective in its ability to effect a myogenic differentiation block can be potentiated by the application of cross-linking monoclonal antibodies. We therefore presume that it is CEA-CEA binding leading to clustering on the cell surface that is required for the differentiation block. Further work has shown that the glycoposphatidyl inositol (GPI) membrane anchor of CEA is also required for the myogenic differentiation block.

The precise subdomains in the N domain of the CEA molecule responsible for intercellular adhesion and for the myogenic differentiation block (and, by implication, other types of differentiation block) have been identified. These are NRQII, starting at amino acid #42 in the N domain of CEA (where the numbering begins at the first amino acid of the mature protein)

- 14 -

which, when deleted or mutated to NRRIV (Q44R&I46V) or DRQII (N42D), abrogate both intercellular adhesion in transfected CHO-derived cells and the myogenic differentiation block; in addition, mutations giving amino acid substitutions at QND, starting at amino acid #80 in the N domain, giving QAD (N81A) or QNN (D82N) completely remove the ability of CEA to block myogenic differentiation without affecting its ability to mediate intercellular adhesion in CHO-derived cells (Figs. 9 and 10). A third subdomain, GYSWYK, starting at amino acid #30 in the N domain of CEA, is under investigation. The subdomains in the NH<sub>2</sub>-terminal N domain of CEA that are required for intercellular adhesion of stable transfectants of CHO-derived LR cells and for the myogenic differentiation block of stable transfectants of rat L6 myoblasts are shown in Fig. 9. The positions of the 2 subdomains in the N domain of CEA that are required for adhesion and differentiation block are shown (top, Fig. 9). The effects of mutations in these subdomains on CEA-mediated adhesion, indicated by the % of cells remaining as single cells after incubation in suspension for 2 hrs, and on CEA-mediated myogenic differentiation block, indicated by the % of nuclei in fused cells, are shown (bottom, Fig. 9). Photomicrographs of L6 transfectants indicated in Fig. 9, showing the extent of myogenic differentiation in some of the subdomain mutants after growth under differentiation conditions are presented in Fig. 10. The control L6 cells transfected with vector alone, L6-Neo, show extensive differentiation, whereas L6 transfected with CEA cDNA (L6-CEA) show none. Deletion of NRQII and especially point mutations at D82 and Q44+I46 show release of the CEA-imposed differentiation block.

- 15 -

Thus the adhesive and differentiation-blocking activities of CEA can be separated, allowing the possibility of precise interference with the differentiation-blocking activity.

5        We thus propose to use peptides or mimetics representing these subdomains or monoclonal antibodies that bind to them that block the necessary CEA-CEA or NCA-NCA intermolecular interactions for the tumorigenic effects of CEA/NCA as agents for clinical use.

10

### 3. Shankless Anchors:

We have shown that the structural features of the CEA molecule required for the differentiation are as follows: first, external domains capable of self  
15 association and, second, attachment of these to the hydrophobic carboxy-terminal domain of CEA; the latter domain is normally cleaved during processing events resulting in the formation of a GPI membrane anchor. Thus the trans-membrane linked BGP $\alpha$  member of the CEA  
20 family, normally without effect on myogenic differentiation, can be converted to one that blocks differentiation by the addition of the CEA GPI domain (Fig. 11). Substitution of the normal trans-membrane domain of the BGP $\alpha$  molecule (Tm), including its  
25 cytoplasmic domain, with the GPI membrane domain of CEA (GPI) converts BGP $\alpha$  from a molecule that has no effect on myogenic differentiation (upper micrograph) to one (denoted BC-2) that inhibits myogenic differentiation completely (lower micrograph). FACS profiles showing  
30 cell surface levels of BGP $\alpha$  and BC-2 indicate equivalent levels of expression (Fig. 11). Strikingly, the GPI membrane-linked NCAM splice isoform, NCAM-125, which has no effect on myogenic differentiation, can also be converted to a molecule with differentiation  
35 blocking capacity by the addition of the CEA GPI domain

- 16 -

(Fig. 12). The GPI-linked NCAM (neural cell adhesion molecule) splice isoform with the muscle-specific domain (MSD), NCAM 125, even at relatively high levels of cell surface expression in rat L6 stable  
5 transfectants, has no effect on myogenic differentiation. Substitution of its own carboxy-terminal GPI-determining domain (open circle) with the GPI domain of CEA (full circle) giving the hybrid construct, NCAM 125-CEA, however, converts it into a  
10 molecule that inhibits myogenic differentiation completely (Fig. 12).

Strategies 1. and 2. depend on interference with the binding domains of CEA which are the self-binding domains naturally associated with the CEA GPI  
15 anchor. The present strategy is targeted to the GPI domain itself. CEA molecules lacking binding domains, consisting of the GPI anchor alone, with little or no attached peptide ("shankless anchors"), can be generated by enzymatic cleavage or by the use of CEA  
20 cDNA constructs with deleted binding domains. These can be applied directly to cells blocked in differentiation by CEA/NCA and, as has been shown for other GPI-linked molecules, should successfully embed themselves from the external milieu into the membrane of the cells.  
25 Inhibition with the differentiation-blocking activity of the endogenous CEA/NCA molecules is anticipated via competition by the CEA shankless anchors for elements of the molecular pathway required for the CEA/NCA effect.

30 The agents described above in routes 1, 2, 3 and 4 of the present invention should cause CEA/NCA over-expressing tumor cells to differentiate terminally, thus removing them as potential colonizing cells in the body.

35

- 17 -

#### 4. Regulation of integrin function

We have recently shown that CEA/NCA over-expression inhibits terminal differentiation in so many different types of cells by perturbing a molecular process common to all, that of interaction with the extra-cellular matrix (ECM). The major class of cellular receptors responsible for ECM interactions are the integrins; integrin-ECM interactions are known to be involved in many types of differentiation, in the maintenance of tissue architecture and in anoikis (apoptosis). The particular integrin disturbed in its function by CEA/NCA expression (but not by BGP or other controls) is  $\alpha_5\beta_1$ , as shown by reversal of the inhibitory effect of CEA/NCA on anoikis of suspended rat L6 myoblasts and human Caco-2 cells by a monoclonal antibody against this integrin. This mAb or peptides/mimetics that mimic its effects on  $\alpha_5\beta_1$  function could be administered to patients bearing CEA/NCA expressing tumors and would be expected to release the differentiation block imposed by CEA/NCA.

#### Development of the present invention over the next year

1. Antisense oligonucleotides and cDNA constructs will be prepared and tested for their ability to reduce the expression of CEA/NCA in SW-1222 (NCA $\uparrow$ ) cells and Caco-2 (CEA/NCA $\uparrow$ ) cells. The effects on the cellular and tissue architecture and tumorigenicity of these transfectants so treated will be measured, expecting a reversal to more normal behaviour.
2. Peptides, and possibly mimetics, against the differentiation-blocking subdomains of CEA will be developed and tested for their ability to release the myogenic differentiation block and to reduce the tumorigenicity of L6 myoblast

- 18 -

transfectants expressing CEA. The peptides/mimetics will also be tested for ability to restore normal cell and tissue architecture and reduce tumorigenicity of SW-1222 (NCA $\uparrow$ ) and Caco-2 (CEA/NCA $\uparrow$ ) cells.

5

3. The proof of concept of shankless anchors will be carried out, i.e. CAE shankless anchors will be prepared and applied to L6 myoblast transfectants expressing CEA, testing for their ability to release the CEA-imposed differentiation block.

10

4. The mAb against  $\alpha_5\beta_1$  will be tested for its ability to reverse all of the effects of CEA expression on the L6 myoblasts, including impairment of binding of ECM and the differentiation block. The test will be extended to SW-1222 (NCA $\uparrow$ ) and Caco-2 (CEA/NCA $\uparrow$ ), looking for restoration of normal cell and tissue architecture.

15

20 The present invention will be more readily understood by referring to the following example which is given to illustrate the invention rather than to limit its scope.

#### EXAMPLE I

#### 25 **Peptide/mimetic, monoclonal antibody or drug screening assay**

L6 rat myoblasts transfected with CEA/NCA cDNA and thereby blocked in their differentiation provide the most sensitive assay for screening agents capable of releasing the differentiation block.

30

1. L6 (CEA/NCA) cells are seeded into tissue culture plates containing multiple wells and cultured until forming a confluent monolayer.

2. The medium is changed to a medium poor in growth factors (DMEM plus 2% horse serum) that

35

- 19 -

stimulates differentiation. At the same time the agent to be tested is added at a series of concentrations to an appropriate number of cultures in the wells.

- 5        3. The culture plate is incubated for 5-7 days. If the agent being tested is unstable, additional agent is added during this incubation period.
- 10       4. At the end of the incubation period, the medium is removed and the cultures stained with hematoxylin. Release of the CEA/NCA-imposed differentiation block is easily assessed by the presence of multinucleated giant cells (see Fig. 10) and quantitated by the percentage of total  
15       nuclei in cells with >3 nuclei.
- 20       5. Agents that give high levels of myogenic differentiation are then tested for effects on human colonocytes aberrantly expressing high levels of CEA/NCA. The simplest assays are the test for formation of glandular structures of polarized cells by SW-1222 I(NCA<sup>↑</sup>) cells in monolayer (see Fig. 2) and the assay for dome formation Caco-2 (CEA-NCA<sup>↑</sup>) cells (see Fig. 4).  
While the invention has been described in con-  
25       nection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and  
30       including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended  
35       claims.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. An inhibiting CEA/NCA sequence, which comprises antisense cDNA sequences which hybridize to at least one domain of CEA/NCA selected from the group consisting of the cDNA sequences of CEA and NCA to reduce the expression of endogenous CEA/NCA when administered to a cancer patient.
2. The inhibiting CEA/NCA sequence of claim 1, wherein said sequence is an antisense cDNA or an antisense oligonucleotide.
3. Anti-CEA/NCA antibodies, which comprises antibodies raised against subdomains of CEA/NCA involved in the differentiation-blocking activity associated with tumorigenicity, wherein said subdomains are selected from the group consisting of the sequences GYSWYK, N<sub>42</sub>RQII, Q<sub>80</sub>ND and other 30 sequences in the N terminal 107 amino acid domain, and sequences in the internal A3BB domain of CEA.
4. Peptides and peptide-derived mimetics, which comprises peptide and peptide-derived mimetics interacting with subdomains of CEA/NCA involved in the differentiation-blocking activity associated with malignant, wherein said subdomains are selected from the group consisting of the sequences GYSWYK, N<sub>42</sub>RQII, Q<sub>80</sub>ND and other 30 sequences in the N-terminal 107 amino acid domain, and sequences in the internal A3BB domain of CEA.



- 21 -

5. A shankless anchor, which comprises a GPI anchor of CEA without the external domains attached to some carboxy terminal amino acids, wherein said GPI anchor interferes with downstream targets of endogenous CEA/NCA molecules to inhibit the differentiation-blocking activity of the endogenous CEA/NCA molecules.


6. A method to restore endogenous integrin function, which comprises the steps of:

- a) administration of monoclonal antibodies that reverse the CEA/NCA-induced changes in integrin function; and
- b) administration of peptides/mimetics that mimics the effect of the mAbs;  
thereby inhibiting the differentiation-blocking activity of the endogenous CEA/NCA molecules.

7. A drug screen assay to determine pharmaceutical agents which are capable of inhibiting the differentiation-blocking activity of the endogenous CEA/NCA molecules, which comprises the steps of:


- a) screening for agents capable of releasing the myogenic differentiation block in rat L6 cells expressing CEA/NCA; and
- b) screening for agents capable of restoring normal cellular and tissue architecture to human Caco-2 colonocytes aberrantly expressing high levels of CEA/NCA.

# **Illustration of Four Routes of Interference With The Tumorigenic Effects of CEA/NCA in Colonic Crypts**




**Fig. 1**

**Overexpression of NCA Blocks The Formation of Glandular-Like Structures of Polarized Cells in Monolayer Culture**



**Fig. 2**

# Overexpression of NCA Blocks Glandular Differentiation of Colonocytes Grown in Collagen Gels



## Overexpression of CEA and NCA Blocks Polarization of Caco-2 Cells




Fig. 3

# Effect of CEA and NCA Overexpression on Dome Formation of Caco-2 Cells




Fig. 4

## Overexpression of NCA Blocks Glandular Differentiation of Colonocytes In Vivo




Fig. 5

# Overexpression of NCA Blocks Anoikis of SW1222 Cells




Fig. 6

**Down-Regulation of CEA in SW1222 Cells (SW-CEA ↓ ) Results  
in a flatter More Normal Appearing Monolayer Morphology**





Fig. 7




# **Effects of Up-Regulation of NCA And Down-Regulation of CEA on Glandular Spheroid Formation in Collagen Gels**



**Fig. 8**

# IDENTIFICATION OF SUBDOMAINS OF CEA MOLECULE AFFECTING INTERCELLULAR ADHESION AND DIFFERENTIATION BLOCK



SUBDOMAINS	MUTATIONS	ADHESION	DIFFERENTIATION
		% Single cells (LR)	% Fusion Index (L6)
-	NONE	17	0
NRQII	NRQII deletion ( $\Delta$ NI)	89	51
"	N42D	65	43
"	I45K	12	0
"	I46V	23	0
"	Q44R&I46V	91	100
QND	D82N	27	100
"	N81A	34	87

Fig. 9

**L6-Neo**



**L6-CEA**



**L6-ΔNICEA**




**L6D82N-CEA**



**L6Q44R&I46V-CEA**




**L6I46V-CEA**



**Fig. 10**

# Effect of Membrane Linkage on Myogenic Differentiation Block



# Effect of Type of GPI Anchor on Myogenic Differentiation Block





Fig. 12

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**